ACCC COVID-19 Resource Center & Listserv
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for the MULTIDISCIPLINARY CANCER CARE TEAM and the PATIENTS they serve since 1997
Meetings & Education
Financial Advocacy & Patient Assistance
SCOS Fellows Travel Award
Patient Advocacy Organizations
State & Federal Resources
Off-Label Use Literature
Find A Clinical Trial
National Professional Organizations
SCOS Corporate Members
Become a Corporate Member
Industry News Archive
FDA Approves Nivolumab for Previously Treated SCLC Patients
On August 17, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo, Bristol-Myers Squibb Co.) for patients with metastatic small cell lung cancer (SCLC) whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy. Approval for this indication has been granted under accelerated approval based on overall response rate (ORR) and duration of response (DOR).
Read the BMS press release here.
Read the FDA announcement her
Tweets by OSSatACCC